Holen Sie sich die Stockscreener-App
2.28
5.39%
-0.13
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX outlines cancer strategy. CytomX Therapeutics stock trades ahead of November 5 results - AD HOC NEWS
Cytomx Therapeutics Stock Price Forecast. Should You Buy CTMX? - StockInvest.us
Cytomx Thera (CTMX-Q) Stock Price and News - The Globe and Mail
CytomX Therapeutics (CTMX) Short Interest & Short Float | Updated Sep 2026 - marketbeat.com
CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions - Simply Wall Street
CytomX Therapeutics Inc (6C1) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare ConferenceSlideshow (NASDAQ:CTMX) 2026-09-10 - Seeking Alpha
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com South Africa
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Australia
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Nigeria
CytomX at cantor healthcare conference: pipeline gains, safety test ahead - investing.com
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com India
CytomX at Wells Fargo conference: epcam bet and cash strength - investing.com
CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
CytomX Therapeutics to Present at Upcoming September Investor Conferences - finance.yahoo.com
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com UK
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - finance.yahoo.com
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ('Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - The Manila Times
FDA Fast Track status comes as CytomX plans a 2027 colorectal cancer study - Stock Titan
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVanna Flow - siam.in
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateProfit Surge Picks - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (CTMX) Climbs 2.68% to $3.45, Trades Within Key Support-Resistance RangeHidden Order - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - marketbeat.com
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CytomX upgrades to speculative Buy on promising cancer drug Varseta-M and expanded Regeneron partnership - Pluang
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Australia
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Nigeria
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Canada
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com India
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com UK
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):